Vertex Pharmaceuticals Income (Loss) from Continuing Operations Before Income Taxes, Domestic remained flat by 0.0% to $705.30M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 306.0%, from -$342.43M to $705.30M. Over 2 years (FY 2023 to FY 2025), Income (Loss) from Continuing Operations Before Income Taxes, Domestic shows relatively stable performance with a -4.4% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Higher values indicate strong domestic operational performance.
The pre-tax income or loss generated specifically from operations within the company's home country. This provides insig...
Standard geographic segment reporting for multinational corporations.
ms_income_before_tax_domestic| FY'23 | FY'24 | FY'25 | |
|---|---|---|---|
| Value | $3.09B | -$1.37B | $2.82B |
| YoY Change | — | -144.3% | +306.0% |